Pembrolizumab (pembro) plus chemotherapy (chemo) as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Phase III KEYNOTE-859 study

被引：46

作者：

Rha, S. Y. ^{[1
]}

Wyrwicz, L. S. ^{[2
]}

Weber, P. E. Y. ^{[3
]}

Bai, Y. ^{[4
]}

Ryu, M. H. ^{[5
]}

Lee, J. ^{[6
]}

Rivera, F. ^{[7
]}

Alves, G. V. ^{[8
]}

Garrido, M. ^{[9
]}

Shiu, K. -k. ^{[10
]}

Fernandez, M. Gonzalez ^{[11
]}

Li, J. ^{[12
]}

Lowery, M. ^{[13
]}

Cil, T. ^{[14
]}

Cruz, F. J. S. M. ^{[15
]}

Qin, S. ^{[16
]}

Yin, L. ^{[17
]}

Bordia, S. ^{[18
]}

Bhagia, P. ^{[18
]}

Oh, D-y. ^{[19
]}

机构：

[1] Yonsei Univ Hlth Syst, Yonsei Canc Ctr, Internal Med, Seoul, South Korea

[2] Mar Sklodowska Curie Natl Res Inst Oncol, Oncol & Radiotherapy, Warsaw, Poland

[3] Univ La Frontera, James Lind Canc Res Ctr, Internal Med, Temuco, Chile

[4] Harbin Med Univ, Canc Hosp, Gastrointestinal Oncol, Harbin, Peoples R China

[5] Univ Ulsan, Asan Med Ctr, Oncol, Coll Med, Seoul, South Korea

[6] Sungkyunkwan Univ, Samsung Med Ctr SMC, Hematol & Oncol, Sch Med, Seoul, South Korea

[7] Hosp Univ Marques de Valdecilla, Med Oncol, Santander, Spain

[8] Hosp Nossa Senhora Conceicao, Med Oncol, Porto Alegre, Brazil

[9] Univ Mayor, Oncol, Santiago, Chile

[10] Univ Coll Hosp NHS Fdn Trust, Oncol, London, England

[11] IMAT Oncomed, Monteria, Colombia

[12] Tongji Univ, Shanghai East Hosp, Med Oncol, Sch Med, Shanghai, Peoples R China

[13] Trinity St James Canc Inst, Med Oncol, Dublin, Ireland

[14] Hlth & Sci Univ, Adana City Hosp, Med Oncol, Adana, Turkiye

[15] Nucleo Pesquisa & Ensino Rede Sao Camilo, Med Oncol, Sao Paulo, Brazil

[16] Canc Ctr Peoples Liberat Army, Med Oncol, Nanjing, Peoples R China

[17] Merck & Co Inc, Biostat & Res Decis Sci, Rahway, NJ USA

[18] Merck & Co Inc, Global Clin Dev, Rahway, NJ USA

[19] Seoul Natl Univ, Internal Med, Coll Med, Seoul, South Korea

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷 / 03期

关键词：

D O I：

10.1016/j.annonc.2023.01.006

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：319 / 320

页数：2

共 50 条

[1] Pembrolizumab (pembro) plus chemotherapy (chemo) for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Updated results from the KEYNOTE-859 study
Rha, Sun Young
Wyrwicz, Lucjan S.
Weber, Patricio Eduardo Yanez
Bai, Yuxian
Ryu, Min-Hee
Lee, Jeeyun
Rivera, Fernando
Alves, Gustavo Vasconcelos
Garrido, Marcelo
Shiu, Kai-Keen
Fernandez, Manuel Gonzalez
Li, Jin
Lowery, Maeve Aine
Cil, Timucin
Cruz, Felipe Melo
Oh, Do-Youn
Yin, Lina
Bordia, Sonal
Bhagia, Pooja
Qin, Shukui
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[2] KEYNOTE-859 update: Pembrolizumab plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer
Ryu, M. H.
Rha, S. Y.
Wyrwicz, L. S.
Weber, P. E. Yanez
Bai, Y.
Lee, J.
Herrero, F. Rivera
Alves, G. V.
Garrido, M.
Shiu, K-K.
Gonzalez Fernandez, M.
Li, J.
Lowery, M. A.
Cil, T.
Cruz, F.
Oh, D-Y.
Yin, L.
Bordia, S.
Bhagia, P.
Qin, S.
ANNALS OF ONCOLOGY, 2024, 35 : S1473 - S1474
[3] Pembrolizumab (Pembro) or placebo (Pbo) plus chemotherapy (Chemo) for advanced HER2-negative gastric/gastroesophageal junction (G/GEJ) adenocarcinoma (KEYNOTE-859): Asia subgroup analysis
Oh, D-Y.
Bai, Y.
Ryu, M. H.
Lee, J.
Li, J.
Luo, S.
Pan, H.
Qu, Y.
Lu, J.
Yang, L.
Yasui, H.
Yabusaki, H.
Yen, C. J.
Chan, W. W. L.
Yamaguchi, K.
Yeh, K-H.
Yin, L.
Bordia, S.
Bhagia, P.
Rha, S. Y.
ANNALS OF ONCOLOGY, 2023, 34 : S1526 - S1526
[4] A randomized, double-blind, phase III study of pembrolizumab plus chemotherapy as first-line therapy in patients with HER2-negative, advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: KEYNOTE-859
Qin, S.
Tabernero, J.
van Cutsem, E.
Fuchs, C. S.
Janjigian, Y. Y.
Bhagia, P.
Li, K.
Adelberg, D.
Bang, Y-J.
ANNALS OF ONCOLOGY, 2020, 31 : S1316 - S1317
[5] Additional data from the KEYNOTE-859 study of pembrolizumab plus chemotherapy versus placebo plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer
Wyrwicz, L.
Oh, D.
Weber, P.
Bai, Y.
Ryu, M.
Lee, J.
Rivera, F.
Alves, G. Vasconcelos
Garrido, M.
Shiu, K.
Fernandez, M. Gonzalez
Li, J.
Lowery, M.
Cil, T.
Cruz, F.
Qin, S.
Yin, L.
Bordia, S.
Bhagia, P.
Rha, S.
ANNALS OF ONCOLOGY, 2023, 34 : S181 - S181
[6] Health-related quality of life (hrqol) analysis from KEYNOTE-859: First-line (1L) pembrolizumab (pembro) plus chemotherapy (chemo) for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) adenocarcinoma
Lowery, M.
Wyrwicz, L.
Oh, D-Y.
Shiu, K. K.
Weber, P. Yanez
Bai, Y.
Lee, J.
Rivera, F.
Alves, G.
Garrido, M.
Fernandez, M. Gonzalez
Li, J.
Cil, T.
Cruz, F.
Qin, S.
Yin, L.
Valderrama, A.
Bordia, S.
Rha, S. Y.
ANNALS OF ONCOLOGY, 2023, 34 : S854 - S855
[7] First-Line Pembrolizumab Plus Chemotherapy for HER2-Negative Advanced Gastric Cancer: China Subgroup Analysis of the Randomized Phase 3 KEYNOTE-859 Study
Qin, Shukui
Bai, Yuxian
Li, Jin
Pan, Hongming
Luo, Suxia
Qu, Yanli
Ye, Feng
Yang, Lin
Liu, Tianshu
Li, Wei
Chen, Xi
Yang, Jianwei
Ying, Jieer
Lin, Xiaoyan
Zhao, Lin
Liang, Xinjun
Mao, Yixiang
Guo, Run
Zuo, Yi
Bordia, Sonal
Li, Shouguo
ADVANCES IN THERAPY, 2025, : 1892 - 1906
[8] KEYNOTE-859: a Phase III study of pembrolizumab plus chemotherapy in gastric/gastroesophageal junction adenocarcinoma
Tabernero, Josep
Bang, Yung-Jue
Van Cutsem, Eric
Fuchs, Charles S.
Janjigian, Yelena Yuriy
Bhagia, Pooja
Li, Kan
Adelberg, David
Qin, Shu Kui
FUTURE ONCOLOGY, 2021, 17 (22) : 2847 - 2855
[9] Pembrolizumab or placebo plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: An updated analysis of KEYNOTE-859 for patients enrolled in Asia.
Yen, Chia Jui
Oh, Do-Youn
Bai, Yuxian
Ryu, Min-Hee
Lee, Jeeyun
Li, Jin
Yang, Lin
Yasui, Hisateru
Yabusaki, Hiroshi
Lam, Ka On
Yamaguchi, Kensei
Yeh, Kun-Huei
Yin, Lina
Leconte, Pierre
Bhagia, Pooja
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 464 - 464
[10] KEYNOTE-859 study of pembrolizumab plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Outcomes in the protocol-specified PD-L1-selected populations
Rha, Sun Young
Wyrwicz, Lucjan
Weber, Patricio Eduardo Yanez
Bai, Yuxian
Ryu, Min-Hee
Lee, Jeeyun
Rivera, Fernando
Alves, Gustavo Vasconcelos
Garrido, Marcelo
Shiu, Kai-Keen
Fernandez, Manuel Gonzalez
Li, Jin
Lowery, Maeve Aine
Cil, Timucin
Cruz, Felipe Melo
Qin, Shukui
Yin, Lina
Bordia, Sonal
Bhagia, Pooja
Oh, Do-Youn
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)

← 1 2 3 4 5 →